Name: LBPS: 4D pharma Latest Stock Price, Analysis, News and Trading Ideas
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing intense market volatility as investors weigh a strong revenue beat against concerns over massive capital expenditures and an impending wave of insider share unlocks. The community is actively debating the stock's valuation, with bulls focused on long-term growth from AI and Starlink expansion, while bears warn of potential downward pressure as insider lock-up periods begin to expire.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are facing significant volatility as investors react to a double earnings beat that fell short of aggressive whisper expectations, while simultaneously digesting competitive headwinds from rival AI infrastructure deals. The community is sharply divided between long-term bulls highlighting strong data center growth and profit-taking bears who point to the stock's elevated valuation and circular financing concerns.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending due to a legal battle with rival Eli Lilly over alleged misleading advertising for weight-loss drugs, combined with heavy community debate regarding pipeline execution and the competitive outlook of its GLP-1 treatments ahead of upcoming earnings. Investors are intensely focused on Wegovy pill prescription trends and long-term valuation concerns as the stock maintains a critical struggle around the psychological support level.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is trending due to heightened volatility as investors debate whether recent price pullbacks represent a major bottom or a continued correction amid shifting geopolitical tensions and fluctuating U.S. inflation data. Community sentiment is sharply divided, with bulls pointing to long-term industrial demand and currency devaluation as catalysts for a potential rally, while bears warn that silver's recent price action signals further downside.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as investors aggressively buy into a broad market rally driven by speculative hope surrounding a potential Iran peace deal and AI-led growth momentum. Despite significant skepticism regarding the validity of these geopolitical headlines and warnings of technical overextension, market participants are actively debating whether this is a genuine breakout toward record highs or an unsustainable euphoria-fueled liquidity trap.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing aggressive bullish momentum, driven by investor optimism surrounding enterprise AI adoption and market speculation regarding potential geopolitical de-escalation in the Strait of Hormuz. While some community members are capitalizing on the rapid recovery, a significant portion of the conversation remains divided between traders riding the AI-driven upside and those warning of overvaluation, Ponzi-like financial engineering, and the risks of chasing a market currently hitting new highs.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the company's aggressive strategy to overhaul its distribution model in China marks a necessary long-term turnaround or a self-inflicted revenue headwind. The community remains deeply divided, with some highlighting the brand's iconic status as a value opportunity while others view the stock as dead weight amid ongoing operational struggles and analyst downgrades.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen is seeing significant community interest driven by impressive revenue growth following the commercial launch of its FDA-approved RRP therapy, PAPZIMEOS. Investors are closely watching for updates on the J-code implementation and clinical progress for the PRGN-2009 program, with many discussing the potential for a long-term valuation shift as the company transitions from a development-stage entity to a commercial biotech.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Investors are closely monitoring SPDR Gold Shares (GLD) as a potential hedge against broader market volatility, with ongoing community debate centered on whether recent price action signifies a durable bottom or a short-term bull trap. Market sentiment is heavily influenced by speculative factors, including shifting expectations for Federal Reserve interest rate policy and geopolitical instability, driving active discussion around gold's role as a safe-haven asset.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors discuss a potential short squeeze and institutional accumulation, fueled by ongoing software sector rotation and speculation surrounding the company's long-term enterprise AI automation strategy. Community members are actively debating the stock's turnaround potential, highlighting strong fundamentals like high cash reserves and recurring revenue while bracing for high volatility ahead of upcoming earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D currently has a pipeline of 15 therapeutic programmes covering autoimmune diseases, CNS disorders and cancer; with two programmes in patient trials, and the expectation to initiate another three programmes over the coming twelve months.

4d Pharma Plc - ADR

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

LBPS4D pharma

Fundamentals

Connect Stocktwits to ChatGPT

Latest LBPS News